Partnership Announcement
On 10 November 2026, Boltz PBC and Excelra disclosed a strategic partnership aimed at enhancing Boltz’s AI‑driven drug discovery platform. The collaboration leverages Excelra’s GOSTAR™ database to train BoltzMol‑1’s ADMET (absorption, distribution, metabolism, excretion, toxicity) models, providing an early‑stage triage layer that filters out chemically unfavorable compounds before they are purchased or synthesized.
GOSTAR™ Data Capabilities
GOSTAR™ supplies curated measurements of kinetic solubility, lipophilicity and Caco‑2 permeability for more than 11 million small molecules. The dataset is ISO 9001‑certified and can be accessed as a standalone application, via APIs, or as a downloadable machine‑learning dataset.
Model Performance and Technical Validation
A recent technical report described a prospective validation in which Boltz evaluated ten challenging targets—most of which were absent from its existing affinity training set. Using only 28 to 96 compounds per target, Boltz confirmed binders or active compounds for six of the targets. This contrasts sharply with conventional high‑throughput screening (HTS), which typically screens thousands to millions of compounds and achieves hit rates often below 0.15%.
The GOSTAR‑trained ADMET models matched or exceeded the performance of the leading open‑source ADMET package when tested on strictly out‑of‑distribution chemistry, delivering the most pronounced improvements in solubility and permeability predictions.
Executive Comments
"GOSTAR™ dataset’s scale helps us build models that generalize to chemistry far outside typical training data. It’s become an important input across our modeling work at Boltz, letting us save a significant amount of time," said Gabriele Corso, Co‑founder and CEO of Boltz PBC.
"We’re proud to support Boltz as they push the frontier of AI‑driven drug discovery. Curated solubility data at this scale is exactly what public sources lack, and what GOSTAR™ was built to provide: a foundation for models that hold up on prospective data, not just retrospective benchmarks," added Anandbir Brar, CEO of Excelra.
About Excelra
Excelra positions itself as a leading data‑science and AI partner to the world’s top life‑science organisations, aiming to make drug discovery and development smarter and faster. Its GOSTAR™ database offers a curated, ISO 9001‑certified view of over 11 million small molecules and their biological properties.
About Boltz PBC
Boltz PBC is an applied‑AI research laboratory and public‑benefit corporation that develops the Boltz family of open and proprietary models for protein‑structure prediction, protein design, and small‑molecule hit discovery. The company’s vision is to make biology programmable and accelerate discovery by keeping frontier capabilities broadly accessible.
Media Contacts
- Excelra: Prashant Sharma, contact@excelra.com
- Boltz PBC: contact@boltz.bio
Disclaimer: This press release is distributed under an arrangement with PRNewswire; PTI assumes no editorial responsibility.